Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Michael D. Jain et al.|Journal of Clinical Oncology|2020Cited by 782
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M. Horwitz, Pierluigi Porcu, Andrew D. Zelenetz et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 141
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Jane Osterson et al.|Blood|2024Cited by 132